Literature DB >> 324660

Gonadal function in Bloom's syndrome.

R Kauli, R Prager-lewin, H Kaufman, Z Laron.   

Abstract

Five patients with Bloom's syndrome aged from 2 8/12 to 27 years, all of whom had hypogonadism, were subjected to an i.v. LHRH test and two of them to an i.m. HCG test. There was increased responsiveness of plasma LH and FSH, indicating that the hypogonadism is primary in nature and of early development. The tubular element of the testis seems to be mainly affected, as indicated by the particularly high FSH response to LHRH stimulation, a history of sterility in the two adult patients and documented azoospermia in one of them. The Leydig cells seem to be less affected and secrete sufficient androgens to enable puberty within acceptable normal limits. Hypogonadism seems to be a major characteristic of Bloom's syndrome.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324660     DOI: 10.1111/j.1365-2265.1977.tb02013.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Sgs1 helicase activity is required for mitotic but apparently not for meiotic functions.

Authors:  A Miyajima; M Seki; F Onoda; M Shiratori; N Odagiri; K Ohta; Y Kikuchi; Y Ohno; T Enomoto
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Non-random chromosomal aberrations in a complex leukaemic clone of a Bloom's syndrome patient.

Authors:  F Shabtai; U H Lewinski; A Meroz; D Klar; M Djaldetti; I Halbrecht
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

Review 3.  Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition.

Authors:  Christopher Cunniff; Jennifer A Bassetti; Nathan A Ellis
Journal:  Mol Syndromol       Date:  2016-11-05

4.  Mammalian BLM helicase is critical for integrating multiple pathways of meiotic recombination.

Authors:  J Kim Holloway; Meisha A Morelli; Peter L Borst; Paula E Cohen
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.